An update from Sanofi ( (SNY) ) is now available.
In February 2025, Sanofi, in collaboration with Teva Pharmaceuticals, presented promising results from the RELIEVE UCCD phase 2b study of duvakitug, a monoclonal antibody for treating ulcerative colitis and Crohn’s disease, at the ECCO Congress in Berlin. The study demonstrated significant clinical and endoscopic improvements over placebo, with plans to initiate a phase 3 program later in 2025, potentially enhancing Sanofi’s position in the inflammatory bowel disease treatment market.
More about Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company focuses on various therapeutic areas, including immunology, oncology, and rare diseases, with a strong emphasis on developing innovative treatments for chronic and complex conditions.
YTD Price Performance: 12.35%
Average Trading Volume: 2,388,017
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $136.6B
Learn more about SNY stock on TipRanks’ Stock Analysis page.